Current immunohistochemical (IHC) and molecular analyses, including RUNX2 [5,11], KPNA2 [5,12], and SATB2 [13,14,15,16,17] as biomarkers, support the osteogenic origin of the tumor and assist in differentiating OS from morphologically similar neoplasms. Here, RUNX2 is linked to neoplasm.